Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application in Pharmacokinetic Studies by Vats, Rahul et al.
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
Simple, Rapid and Validated LC Determination of 
Lopinavir in Rat Plasma and its  
Application in Pharmacokinetic Studies 
Rahul VATS, Aditya Narasimha MURTHY, Punna Rao RAVI * 
BITS-Pilani Hyderabad Campus, Jawaharnagar, Ranga Reddy (Dist.), Andhra Pradesh, India. 
* Corresponding author. E-mails: rahulvats1983@gmail.com (R. Vats), adityamurthy1212@gmail.com  
(A. N. Murthy), rpunnarao@gmail.com or rpunnarao@bits-hyderabad.ac.in (P. R. Ravi) 
Sci Pharm. 2011; 79: 849–863        doi:10.3797/scipharm.1107-24 
Published:   September 17
th 2011      Received:   July 21
st 2011 
Accepted:   September 17
th 2011 
This article is available from: http://dx.doi.org/10.3797/scipharm.1107-24 
© Vats et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
Lopinavir is a new specific and potent HIV-1 protease inhibitor. A simple and 
rapid Reverse Phase High-Performance Liquid Chromatographic method using 
UV detection was developed and validated for the analysis of lopinavir in rat 
plasma under isocratic conditions. The method involves a single step protein 
precipitation technique. The detector response was linear over  the 
concentration range of 250 to 4000 ng mL
−1. High recovery ranging from 97.5 to 
101.2 percent was obtained which precludes the use of internal standard. The 
developed method was validated as per standard guidelines. Validation of the 
developed method demonstrated accuracy, precision and selectivity of the 
proposed method. The drug was found to be stable under various processing 
and storage conditions. This rapid and cost-effective method was successfully 
applied in the estimation of lopinavir and determination of various 
pharmacokinetic parameters during post intravenous bolus administration of the 
drug in rats. The developed method can be suitably employed in preclinical 
pharmacokinetic evaluation of new formulations designed to improve the 
bioavailability of lopinavir. 
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Introduction 
Lopinavir (LPV) is a potent HIV protease inhibitor (PI) and a key ingredient of Highly Active 
Anti-Retroviral Therapy (HAART) [1]. LPV was developed by Abbott Laboratories to 
improve pharmacokinetics and to reduce HIV resistance of the company's earlier protease 
inhibitor, Ritonavir (RTV) [2]. LPV has low oral bioavailability when administered alone 
because of poor solubility, high first pass metabolism [3] and P-gp efflux [4]. RTV is co-
administered with LPV orally in HAART in order to improve the bioavailability of LPV. RTV 
increases bioavailability of LPV due to its inhibitory effects on gut and liver Cytochrome 
(CYP) P450 enzymes and permeability glycoprotein (P-gp) efflux system [5].  
LPV (Fig.  1)  is chemically designated as  (2S)-N-[(1S,3S,4S)-1-benzyl-4-{[(2,6-dimethyl-
phenoxy)acetyl]amino}-3-hydroxy-5-phenylpentyl]-3-methyl-2-(2-oxotetrahydropyrimidin-













Fig. 1.   Chemical structure of LPV 
Several research groups have been working on the development of novel delivery systems 
containing LPV alone in the effective treatment of HIV/AIDS. Such delivery systems will 
avoid heavy pill burden of LPV and RTV co-formulation, and improve patient compliance 
and adherence to therapy which are very vital for treatment against HIV/AIDS. In line with 
this, researchers have tried to improve solubility and bioavailability of LPV using 
microparticulate and nanocarrier systems  [7, 8].  Agarwal and co-workers  have tried 
prodrug approach for LPV [9]. Outcome of improving bioavailability of LPV using novel 
drug delivery systems containing LPV alone have been positive in preclinical studies, 
conducted on rats and mice [10]. Such research endeavors need a simple, rapid and cost-
effective bioanalytical method to quantify the LPV concentration in rat plasma. 
Analytical methods for PIs like amprenavir, indinavir, nelfinavir, ritonavir and saquinavir 
have been reported in human plasma and/or other biological matrices [11–21]. 
Simultaneous methods for estimation of LPV in combination with various PIs in human 
plasma, mainly by liquid chromatography tandem mass spectrometry (LC-MS), have been 
reported [22–29].  High-Performance Liquid Chromatographic (HPLC)  methods  with UV 
detection have also been  explored successfully for simultaneous determination  of LPV 
with other PIs using isocratic as well as gradient elution techniques [30, 31]. A method for 
estimation of LPV alone in human plasma matrix using HPLC system has been validated 
[32].   Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application …  851 
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Different sample preparation techniques like protein precipitation, liquid-liquid extraction 
[23–25] and solid phase extraction [22] have been explored for analysis of various PIs. 
Among the reported techniques,  protein precipitation technique is considered to be a 
simple, fast and cost-effective technique for extraction of drug from plasma matrix [28].  
Although bioanalytical methods reported for estimation of LPV are found to be very 
sensitive, precise and accurate, they use costly LC-MS techniques and involve tedious 
and time consuming sample preparation steps. Extensive literature survey did not reveal 
any bioanalytical method for estimation of LPV in rat plasma which can be useful for in 
vivo  pharmacokinetic evaluation of drug delivery systems containing LPV alone in rat 
models. Therefore it was envisaged to develop a simple, rapid, sensitive, accurate and 
reliable HPLC method for estimation of LPV in rat plasma.  
This paper deals with development and validation of a HPLC method, with UV detection, 
for determination  of  LPV in rat plasma using protein precipitation technique.  The 
developed HPLC method was used in the  quantification of LPV in plasma samples 
obtained from in vivo pharmacokinetic studies in rats.  
Experimental 
Chemicals and Reagents  
LPV  was  obtained as gift  sample  from Matrix Laboratories, India. Acetonitrile (HPLC 
grade), methanol  (HPLC grade) and ammonium acetate (LiChropur
®) were purchased 
from Merck laboratories, India.  Ethanol and polyethylene glycol (PEG) 400 were 
purchased from S.D. Fine Chem. Ltd., India. Milli-Q water purification system (Millipore, 
USA) was used for obtaining high quality HPLC grade water. 
Instruments 
The liquid chromatography system employed was Shimadzu HPLC (Shimadzu, Japan) 
with solvent delivery system of two pumps (Model LC-20AD,  Prominence Liquid 
Chromatograph, Shimadzu, Japan), an auto injector (Model SIL-20A HT, Prominence Auto 
Sampler, Shimadzu, Japan) and photo diode array (PDA) UV detector (Model SPD-M20A, 
Prominence Diode Array Detector, Shimadzu, Japan). Data collection and integration was 
accomplished using LC Solutions, 1.25 version software.  
Other instruments used in the method development and validation include vortex mixer 
(Model VX-200, Labnet International Inc., USA),  sonicator (Model SONICA
®  2200 MH, 
Soltec, Italy), refrigerated  centrifuge (Model C-24 BL,  Remi, India)  and deep freezer 
(Model BFS-345-S, Celfrost Innovations Pvt. Ltd., India). pH meter (Model pHTestr 30, 
Eutech Instruments, Singapore) was used for measuring pH of all buffer systems. 
Membrane filters of 0.22 µm (Millipore, USA) were used for filtration of aqueous phase 
used in the mobile phase system.  
Chromatographic Conditions 
An endcapped C18 reverse phase (RP) column (Luna
®, 250 mm long and 4.6 mm internal 
diameter, particle size 5 µm, Phenomenex, USA) equipped with a guard column of same 
packing material was used for the study. The isocratic mobile phase consisted of an 
aqueous phase (10 mM ammonium acetate, pH 6.5) and acetonitrile (35:65 v/v). Buffer 852  R. Vats, A. N. Murthy, and P. R. Ravi:   
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was filtered through 0.22 µm Millipore membrane filter. The HPLC system was stabilized 
for 1 h at 1 mL min
−1 flow rate, through baseline monitoring prior to actual analysis. LPV 
was monitored at wavelength of 210 nm. An injection volume of 100 µL was optimized for 
final method. 
Collection of Blood and Separation of Plasma 
Blood was collected from retro-orbital plexus of Wistar rats (Raj Biotech, India) weighing 
between 180 to 220 g. Prior permission was obtained for all experiments involving animals 
from the Institutional Animal Ethics Committee. Clear supernatant plasma was separated 
from blood after the centrifugation at 3400 rpm, 4° C, for 10 min. Samples were kept at 
−20 °C till further analysis.  
Method Development 
In the process of analytical method development for LPV, mobile phase composition and 
flow rate were optimized by trying different aqueous phase and non-aqueous phase 
combinations at different flow rates. Various buffers with different pH and in varying 
compositions with acetonitrile and/or methanol were investigated.  
Mobile phase composition and flow rate were finally selected based on the criteria of peak 
properties (retention time and asymmetric factor), sensitivity (height and area), ease of 
preparation and applicability of the method for in vivo studies in rats. 
Calibration Curve  
Primary stock solution of LPV (1 mg mL
−1) was prepared in volumetric flask by dissolving 
accurately weighed amount of LPV in methanol. Secondary stock solutions of LPV, 
analytical standards for studying the absolute recovery of plasma standards (250, 500, 
1000, 1500, 2000, 2500, 3000, 4000 ng mL
−1) and analytical quality control samples for 
studying the absolute recovery of plasma quality control samples (800, 1600, 3200 ng 
mL
−1) were prepared by making appropriate dilutions in methanol.  
Plasma calibration standards  and  plasma  quality control samples were prepared by 
spiking 10 µL of appropriate standard solutions of LPV in 90 µL of drug-free rat plasma to 
obtain final concentrations of 250, 500, 1000, 1500, 2000, 2500, 3000, 4000 ng mL
−1 for 
calibration curve and 800, 1600 and 3200 ng mL
−1 for lower quality control (LQC), medium 
quality control (MQC) and higher quality control (HQC) samples,  respectively.  Blank 
sample was prepared by spiking 10 µL of methanol (drug diluent) in 90 µL of blank 
plasma. All solutions were stored at 4 °C until further use. 
Extraction Technique 
A simple, single-step protein precipitation method was followed for extraction of LPV from 
Wistar rat plasma. 100 µL of drug spiked plasma sample was pipetted into a RIA vial and 
350 µL of acetonitrile (protein precipitating solvent) was added to it and vortex mixed for 
2 min. Samples were then centrifuged  at  9000 rpm at 4 °C  for 20 min. From the 
centrifuged samples 300 µL of supernatant was transferred to a sample loading vial and 
injected into the HPLC system.  
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Calibration and Calculation Procedures 
Method Validation 
The developed method was validated statistically as per guidelines given by International 
Conference on Harmonization [33] and United States Pharmacopoeia [34]. Various 
validation parameters of the developed method were determined using following 
procedures: 
Selectivity 
Selectivity of the method can be defined as non-interference by the proteins and other 
impurities present in the bio-matrix at the retention time shown by LPV. Six different lots of 
drug-free rat plasma samples were extracted and analyzed for assessment of specificity 
and selectivity. Overlaid chromatograms of blank plasma, in vivo  test sample,  plasma 
calibration standard (1500 ng mL
−1) and aqueous standard (3200 ng mL
−1) are shown in 
Fig. 2. 
Linearity 
Plasma calibration standards were prepared and analyzed in five independent runs. Daily 
standard curves were constructed using the observed peak area to that of nominal 
concentration. Unknown concentrations were computed from the linear regression 
equation of the peak area against the concentration. Calibration curve was constructed 
from a blank sample (plasma sample processed without drug) and eight non-zero 
concentrations ranging from 250  ng mL
−1  to 4000  ng mL
−1.  The data is presented in 
Table 1.  
Accuracy 
For determining the accuracy of the proposed method, different quality control (QC) levels 
of LPV in plasma (LQC = 800 ng mL
−1, MQC = 1600 ng mL
−1 and HQC = 3200 ng mL
−1) 
were prepared independently and analyzed (n = 6). The data is presented in Table 2. 
Precision 
Repeatability was determined by analyzing all three QC levels of drug concentrations. 
Inter-day and intra-day variation and analyst variations were studied to determine 
intermediate precision of the proposed method. Three QC levels of drug concentrations in 
triplicates were prepared twice in a day and studied for intra-day variation (n = 6). The 
same protocol was followed for three different days to study inter-day variation (n = 18). 
The percent relative standard deviation (%RSD)  was calculated from the predicted 
concentrations obtained by regression equation. The data is presented in Table 3. 
Sensitivity 
Limit of quantification (LOQ) is defined as minimum concentration of LPV in plasma 
sample that can be quantified with less than 20% RSD [33]. In order to determine LOQ, six 
independent plasma samples containing 250 ng mL
−1 of LPV were prepared and analyzed 
using developed method. The peaks were integrated and concentrations were calculated 
using calibration equation. Mean concentration and  %RSD  for these six values were 
determined. 854  R. Vats, A. N. Murthy, and P. R. Ravi:   
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Recovery 
Recovery of the drug was determined by comparing the area obtained from plasma 
(extracted)  samples with analytical  standard (unextracted) samples. For the recovery 
experiment, plasma extracted samples were prepared by spiking LPV at three different 
concentration levels (LQC, MQC and HQC) in triplicate. Precision of LPV recovery at each 
level (n = 3) was determined. Results obtained are presented in Table 4.  
Stability 
Freeze-thaw stability of LPV in rat plasma was determined using three QC (LQC, MQC 
and HQC) samples for  three  freeze-thaw  cycles.  Total of four sets were prepared in 
triplicates and one set of the prepared concentrations was analyzed on the day of 
preparation (no freeze-thaw cycle) and the remaining three sets were frozen at −20 °C for 
24 h. Frozen samples were thawed by keeping the sealed tubes at room temperature for 
at least 1 h. One set in triplicate was analyzed and the remaining two sets were kept at 
−20  °C for freezing and were analyzed after two and three freeze-thaw cycles. The 
percentage deviation from the mean concentrations observed on day of preparation was 
calculated and is presented in Fig. 3a.  
Long-term stability of LPV in rat plasma was determined by preparing three QC samples 
(LQC, MQC and HQC). A total of four sets were prepared in triplicates and one set of the 
prepared concentrations was analyzed on the day of preparation. The remaining three sets 
were frozen at –20 °C. One set each of stored samples was analyzed after 3, 7 and 15 
days of sample preparation by thawing them at room temperature. The percentage 
deviation from the mean concentrations observed on day of preparation was calculated 
and the values obtained are shown in Fig. 3b. 
Post extraction stability of the processed samples of LPV in rat plasma was investigated 
by preparing five sets of QC samples (LQC, MQC and HQC) in triplicates. Processed 
samples were kept in the sample rack of auto sampler and samples were analyzed in 
triplicates every 6 h for 24 h period on the day of preparation. The percentage deviation 
from the mean concentrations observed at zero time was calculated. Results obtained are 
shown in Fig. 3c. 
Pharmacokinetic Study 
LPV formulation for intravenous (IV) bolus administration was prepared by dissolving the 
drug in solvent mixture of ethanol,  PEG 400 and water (10:40:50) just before the 
commencement of study. Formulation was administered through tail vein in male Wistar 
rats (n = 6), weighing 180 to 220 g, at a dose of 5 mg kg
−1 [35]. Blood samples were drawn 
from retro-orbital plexus of Wistar rats at 0.083, 0.167, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 
h post dose in microfuge tube pretreated with sodium citrate solution  (3.8%  w/v).  A 
baseline blank plasma sample was drawn from each animal before drug administration. All 
samples were processed according to the procedure described earlier and analyzed using 
the validated HPLC method. 
Various  pharmacokinetic parameters were calculated from measured LPV  plasma 
concentrations verses time profiles after IV bolus administration using non-compartmental 
model  and compartmental models in WinNonlin Professional software (Version 4.0, 
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Results and Discussions 
Method Development 
Mobile phase consisting of aqueous phase (10 mM ammonium acetate, pH 6.5) and 
acetonitrile (35:65 v/v) at a flow rate of 1 mL min
−1 was selected as optimal condition for 
the developed method. With optimized mobile phase condition, retention time of LPV was 
found to be 13.5 ± 0.15 min with an asymmetric factor of 1.21 ± 0.10. Retention time of 
LPV was increased to 21.02 min with decrease in acetonitrile composition from 65% to 
50% v/v and showed diminished height, whereas the same composition of methanol (65% 
v/v) showed peak broadening and increased retention time. It was found that increase in 
pH  decreases  the  retention time of LPV.  Sharp and symmetrical peak shape with 
reasonable retention time was observed in range of pH 6.5 to 7.0. It was observed that 10 
mM ammonium acetate provided a pH value of 6.5. Hence, it was chosen as buffer without 
further alteration in the composition.  
Method Validation 
Selectivity 
Simple and efficient one-step precipitation technique was found to be suitable for 
estimation of LPV in rat plasma. No interference was observed from endogenous protein 
impurities in processed test samples as well as blank plasma sample at retention time of 
the drug as shown in Fig. 2. Thus, the proposed method was found to be specific and 
selective for the estimation of LPV in rat plasma. 
 
Fig. 2.   Overlaid chromatograms of (a) blank plasma, (b) in vivo test sample, (c) plasma 
calibration standard (1500 ng mL
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Linearity  
Different concentrations and their corresponding areas are shown in Table 1. At all the 
concentration levels, %RSD did not exceed 5.93. The plasma calibration curve was linear 
over the calibration range of 250 ng mL
−1 to 4000 ng mL
−1. According to linear regression 
analysis, the slope (± standard error) and intercept (± standard error) were found to be 
90.34 (± 0.87) and 2475.66 (± 532.97), respectively, with a regression coefficient value of 
0.996. Lower values of standard error of estimate (5.63) and MSSR (1.95 × 10
−4) indicates 
high precision of the developed method. Lower Fcal value of 0.039 in comparison to Fcrit 
(5,35) value of 2.48 at P < 0.05, further confirmed precision of the proposed method. 







b)  % RSD




250    23612.5 ± 1400.78  5.93  100.32 ± 3.91 
500  48157.0 ± 660.44  1.37    99.89 ± 2.32 
1000  100514.5 ± 3517.86  3.50    99.19 ± 1.44 
1500  130077.0 ± 2839.74  2.18    98.92 ± 1.08 
2000  186722.5 ± 4951.87  2.65    99.50 ± 1.32 
2500  231054.0 ± 9192.39  3.98    99.19 ± 1.11 
3000  266898.0 ± 9779.29  3.66    98.96 ± 1.02 
4000  367433.5 ± 1402.19  0.38    98.95 ± 0.94 
a Each value is mean of five independent determinations (n = 5); 
b Standard deviation; 
c Percentage relative standard deviation; 
d Percent drug recovery = [(Peak area of 
plasma standard/peak area of analytical standard of same concentration) ×100]. 
 
Accuracy 
All three quality control samples (LQC = 800 ng mL
−1, MQC = 1600 ng mL
−1 and HQC = 
3200 ng mL
−1) showed an accuracy ranging from −1.37% to 1.47% with maximum %RSD 
of 4.78 across all the QC levels, establishing the accuracy of method for LPV estimation in 
rat plasma (Table 2).  




−1)  Mean 
accuracy
e 




LQC (800 ng mL
−1)  737–842    789.00 ± 37.74  4.78  −1.37 
MQC (1600 ng mL
−1)  1608–1640  1623.46 ± 12.17  0.75  1.47 
HQC (3200 ng mL
−1)  3168–3247  3219.54 ± 27.72  0.86  0.61 
a Each value is mean of six independent determinations (n = 6); 
b Predicted concentration of 
LPV was calculated by linear regression equation; 
c Standard deviation; 
d Percentage relative 
standard deviation; 
e Accuracy is given in relative error % =[100 × (predicted concentration – 
nominal concentration)/nominal concentration)]. 
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Precision 
In a repeatability study, %RSD ranged from 0.32 to 4.96 across all QC samples (Table 3). 
The  %RSD values for intra-day variation were not more than  4.96  and for inter-day 
variation were less than 4.73  (Table 3). Acceptable %RSD values indicated the 
repeatability and intermediate precision of the method. 
Tab. 3.   Results of intermediate precision study in Wistar rat plasma 
Level 
Intra-day repeatability (%RSD
a) (n = 3)  Inter-day 
repeatability 
(%RSD
a) (n = 18)  Day-1  Day-2  Day-3 
LQC  4.37  3.30  4.34  4.73  4.43  4.21  4.96 
MQC  0.32  2.17  1.89  1.44  0.43  1.30  0.63 
HQC  1.03  0.69  0.60  1.57  0.57  0.46  0.80 
a Percentage relative standard deviation. 
 
Sensitivity 
The mean percentage accuracy of six independent samples of 250 ng mL
−1, calculated 
against calibration equation and was found to be 93.1 with %RSD value of 4.88. Hence, 
the concentration of 250 ng mL
−1 was considered as lowest limit of quantification (LLOQ) 
for the proposed method. 
Recovery 
The absolute recovery of LPV from the spiked rat plasma samples, when compared with 
analytical standards of same concentration, was within 97.5% to 100.19% with %RSD less 
than 4.03 at each concentration levels. The high (nearly 100%) mean percent recovery 
values (Table 4)  which precludes the  use of internal standard  and low %RSD values 
(%RSD < 5.0) established the extraction efficiency of the selected solvent for precipitation 
and also robustness of the method. 
In the HPLC methods reported by Usami et al. and Faux et al. for estimation of LPV in 
human plasma, sample preparation involved liquid-liquid extraction and solid-phase 
extraction methods, respectively [32, 33]. Such sample preparation methods involve many 
processing steps which are complex and time-consuming and require costly solvents/solid-
phase extraction cartridges. Internal standard was also used in both the methods. Based 
on the reported methods, plasma sample of at least 500 µL is required in sample 
preparation. To obtain 500 µL of plasma a minimum of 1 mL blood is required to drawn, at 
each time point, from subjects involved in the in vivo  study. Therefore the reported 
methods are not suitable in preclinical pharmacokinetic evaluation of formulations 
containing LPV.  858  R. Vats, A. N. Murthy, and P. R. Ravi:   







Fig. 3.   Stability study of LPV in rat plasma (a) Freeze thaw stability; (b) Post extraction 
stability; (c) Long term stability. Each point represents mean of three 
independent determinations 
Tab. 4.   Absolute recovery of LPV from plasma samples following protein precipitation 
extraction method 
Nominal concentrations (ng mL




800 (LQC)    99.32 ± 4.01  4.03 
1600 (MQC)    97.50 ± 1.32  1.35 
3200 (HQC)  100.19 ± 1.44  1.44 
a Percent drug recovery = [(Peak area of plasma standard/peak area of analytical standard of 
same concentration) ×100]; 
b Standard deviation; 
c Percentage relative standard deviation.   Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application …  859 
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Stability 
The stability of LPV in rat plasma was evaluated using QC samples under different stress 
conditions and the results obtained are shown in Fig. 3. In freeze-thaw stability, no 
significant degradation of LPV was observed up to three cycles over a period of three 
days. The deviation from the zero time concentration was found to be less than 8.0% at 
the end of three freeze-thaw cycles as shown in Fig. 3a. In post extraction stability study of 
the processed samples, LPV was found to be stable for 24 h, with a maximum deviation of 
less than 2.0% from the zero time concentration as shown in Fig. 3b  
In long-term stability studies, LPV was found to be stable for 15 days when stored at 
−20 °C. The deviation in recoveries of LPV after analysis at 3, 7 and 15 days of sample 
preparation was found to be within acceptable limits (Fig. 3c). The results of this study 
indicated that storage temperature of −20 °C was adequate for storing the samples for at 
least 15 days. 
Pharmacokinetic Application 
The developed and validated HPLC method was applied to determine the pharmacokinetic 
parameters following IV bolus administration of LPV formulation in rats. The mean plasma 
concentration versus time profile of LPV obtained following the IV bolus administration is 
given in Fig. 4. 
 
 
Fig. 4.   The mean plasma concentration versus time profile of LPV in rats after 
intravenous bolus administration of the drug (5 mg kg
−1, n = 6) 
Concentration = 3168.7 e-0.84t 
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The time course of plasma drug concentration was found to follow a mono-exponential 
equation, Concentration = 3168.7 e
−0.84t, with a good correlation coefficient (r
2 = 0.999) 
indicating that the drug follows one compartment open model in rats. The pharmacokinetic 
parameters obtained from the study using non-compartmental and compartmental analysis 
were area under the curve (AUC) = 3850.33 ± 263.87 h ng mL
−1, area under the first-
moment curve (AUMC) = 4403.07 ± 171.33 h
2 ng mL
−1, mean retention time (MRT) = 1.15 
± 0.05 h, concentration at time zero (Co) = 3168.68 ± 289.88 ng mL
−1, elimination half-life 
(t½) = 0.82 ± 0.03 h, volume of distribution (Vss) = 1592.09 ± 146.44 mL kg
−1 and total 
plasma clearance (CLs) = 1344.79 ± 4.40 h
−1 mL kg
−1. 
Samples collected till 3 h (approximately equal to 4 times half-life of drug) post IV bolus 
administration of the drug were analyzed in the study indicating the sensitivity and 
applicability of the proposed HPLC method in pharmacokinetic studies of the drug in rats.  
Conclusions 
The developed and validated HPLC method for estimation of LPV in Wistar rat plasma was 
found to be rapid, precise, specific, reproducible and cost-effective. Recovery of LPV from 
plasma samples by protein precipitation technique using acetonitrile was found to be 
efficient. In addition, the drug was found to be stable under various processing and storage 
conditions. The method allows high sample throughput due to simple procedure for sample 
preparation  and relatively short run time.  The method was successfully employed in 
determining the pharmacokinetic parameters of the drug following IV bolus administration 
in rats.  
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